Scientific Publications

Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside. Gabizon A, Shmeeda H, Tahover E, Korneb G, Patil Y, Amitay Y, Ohana P, Sapir E, Zalipsky S Advanced Drug Delivery Review 154-155:13-26. doi: 10.1016/j.addr.2020.07.027. Epub 2020 Aug 7


Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. Gabizon A, Tahover E, Golan T, Geva R, Perets R, Amitay Y, Shmeeda H, Ohana P Investigational New Drugs 38(5):1411-1420. doi: 10.1007/s10637-020-00897-3. Epub 2020 Jan 18


Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-c prodrug (Promitil): mechanistic basis and preliminary clinical experience. Tahover E, Bar-Shalom R, Sapir E, Pfeffer R, Nemirovsky I, Turner Y, Gips M, Ohana P, Corn BW, Wang AZ, Gabizon A Front Oncol., 8:544  doi: 10.3389/fonc.2018.005442018


Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). Patil Y, Shmeeda H, Amitay Y, Ohana P, Kumar S, Gabizon A Nanomedicine, 14 (4): 1407-1416, 2018


Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. Patil Y, Amitay Y, Ohan P, Shmeeda H, Gabizon A. J Control Release 225:87-95, 2016


Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy. Wei XPatil Y , Ohana PAmitay YShmeeda HGabizon A Barenholz Y Mol Pharm 14(12): 4339-4345, 2017


Preclinical Evaluation of Promitil, A Novel Nanoparticle Formulation of Mitomycin C, in Chemoradiation Therapy.Tian X, Nabeel H, Wagner KT, Nguyen M, Min Y, Sethi M, and Wang AZ. International Journal of Radiation Oncology, 90 (1):S803, 2014.


Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. Tian X, Warner SB, Wagner KT, Caster JM, Zhang T, Ohana P, Gabizon AA, Wang AZ. Int J Radiat Oncol Biol Phys.;96(3):547-55, 2016


Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil®): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues. Amitay Y, Shmeeda H, Patil Y, Gorin J, Tzemach D, Mak L, Ohana P, Gabizon A. Pharm Res - 33(3): 686-700, 2016


Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients Golan T , Grenader T, Ohana  P, Amitay Y, Shmeeda H, La-Beck  NM, Tahover E , Berger R & Gabizon AA Cancer Medicine 4(10): 1472-83, 2015


Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S. J Control Release, 160(2):245-53, 2012.


Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action. Zalipsky S, Saad M, Kiwan R, Ber E, Yu N, Minko T. J Drug Target, 15(7-8):518-30, 2007.


Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S. Clin Cancer Res, 12(6):1913-20, 2006.